Published Online:7 Feb 2007https://doi.org/10.2217/14622416.8.2.141
Abstract
The enzyme folylpoly-γ-glutamase synthethase (FPGS) plays an important role in the intracellular polyglutamation of the disease-modifying antirheumatic drug methotrexate (MTX) and the length of the polyglutamated MTX product correlates with the time that MTX resides in the cell. The glutamates are released from MTX by activity of the enzyme γ-glutamyl-hydrolase (GGH), thereby allowing the efflux of MTX. GGH 452C>T has been associated with decreased catalytic activity and higher accumulation of long-chain MTX-polyglutamate. However, single nucleotide polymorphisms (SNPs) in FPGS and GGH genes have not yet been explored for association with MTX efficacy or toxicity. We selected for SNPs with frequencies higher than 10% or, in case of FPGS 114G>A, causing an amino acid change with no known frequencies. In this study, frequencies of two SNPs in FPGS (1994A>G and 114G>A, rs10106 and rs10760502, respectively) and GGH genes (452C>T and 16T>C, rs11545078 and rs1800909, respectively), were determined using a newly developed method in rheumatoid arthritis patients (n = 352) and in a group of healthy controls (n = 360). Next, the SNPs were associated with response to MTX in rheumatoid arthritis patients treated with MTX monotherapy. In rheumatoid arthritis patients, allele frequencies of FPGS 1994A>G were 0.534 (A) and 0.466 (G), and for FPGS 114G>A 0.714 (G) and 0.286 (A). Allele frequencies of GGH 16T>C were 0.737 (T) and 0.263 (C) and for GGH 452C>T 0.912 (C) and 0.088 (T). No significant differences in allele frequencies between rheumatoid arthritis patients and healthy controls were found. In addition, the SNPs were not associated with good clinical response to MTX. Only patients with the GGH 16C-allele and one or no copies of the GGH 452C-16T haplotype were associated with good clinical improvement at 3 months upon treatment with MTX. No associations with efficacy at 6 months and MTX-induced toxicity were found. Therefore we conclude that despite the positive association of the GGH 16C-allele and one or no copies of the GGH 452C-16T haplotype with good clinical improvement at 3 months upon treatment with MTX, the tested SNPs in GGH and FPGS genes are suggested not to be clinically important for MTX treatment outcome.
Keywords:
Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Bibliography
- 1 Weinblatt ME, Coblyn JS, Fox DA et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med.312,818–822 (1985).
- 2 Kremer JM, Lee JK: The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum.29,822–831 (1986).
- 3 Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol.21,S179–S185 (2003).
- 4 Aletaha D, Smolen JS: The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford)41,1367–1374 (2002).
- 5 Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C: Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford)39,975–981 (2000).
- 6 Dervieux T, Furst D, Lein DO et al.: Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann. Rheum. Dis.64,1180–1185 (2005).
- 7 Masson E, Relling MV, Synold TW et al.: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J. Clin. Invest.97,73–80 (1996).
- 8 Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, Witte A, Beaulieu D: Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood76,44–49 (1990).
- 9 Galivan J, Ryan T, Rhee M, Yao R, Chave K: Glutamyl hydrolase: properties and pharmacologic impact. Semin. Oncol.26,33–37 (1999).
- 10 Rhee MS, Lindau-Shepard B, Chave KJ, Galivan J, Ryan TJ: Characterization of human cellular γ-glutamyl hydrolase. Mol. Pharmacol.53,1040–1046 (1998).
- 11 Panetta JC, Wall A, Pui CH, Relling MV, Evans WE: Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of γ-glutamyl hydrolase activity. Clin. Cancer Res.8,2423–2429 (2002).
- 12 Longo GS, Gorlick R, Tong WP, Lin S, Steinherz P, Bertino JR: γ-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol. Res.9,259–263 (1997).
- 13 Dervieux T, Furst D, Lein DO et al.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum.50,2766–2774 (2004).
- 14 Urano W, Taniguchi A, Yamanaka H et al.: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics12,183–190 (2002).
- 15 Wessels JA, Vries-Bouwstra JK, Heijmans BT et al.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum.54,1087–1095 (2006).
- 16 Chave KJ, Ryan TJ, Chmura SE, Galivan J: Identification of single nucleotide polymorphisms in the human γ-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene319,167–175 (2003).
- 17 Dervieux T, Kremer J, Lein DO et al.: Contribution of common polymorphisms in reduced folate carrier and γ-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics14,733–739 (2004).
- 18 Cheng Q, Wu B, Kager L et al.: A substrate specific functional polymorphism of human γ-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics14,557–567 (2004).
- 19 Angelis-Stoforidis P, Vajda FJ, Christophidis N: Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin. Exp. Rheumatol.17,313–320 (1999).
- 20 Aghi M, Kramm CM, Breakefield XO: Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J. Natl Cancer Inst.91,1233–1241 (1999).
- 21 Odin E, Wettergren Y, Nilsson S et al.: Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin. Cancer Res.9,6012–6019 (2003).
- 22 Wettergren Y, Odin E, Nilsson S, Willen R, Carlsson G, Gustavsson B: Low expression of reduced folate carrier-1 and folylpolyglutamate synthase correlates with lack of a deleted in colorectal carcinoma mRNA splice variant in normal-appearing mucosa of colorectal carcinoma patients. Cancer Detect. Prev.29,348–355 (2005).
- 23 Stranzl T, Wolf J, Leeb BF, Smolen JS, Pirker R, Filipits M: Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis. Clin. Exp. Rheumatol.21,27–32 (2003).
- 24 Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum.52,3381–3390 (2005).
- 25 Arnett FC, Edworthy SM, Bloch DA et al.: The American Rheumatism Association (1987) revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum.31,315–324 (1988).
- 26 van Gestel AM, Prevoo ML, 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum.39,34–40 (1996).
- 27 van der Heijde DM, van 't HM, van Riel PL, van de Putte LB: Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J. Rheumatol.20,538–541 (1993).
- 28 Westendorp RG, Langermans JA, Huizinga TW et al.: Genetic influence on cytokine production and fatal meningococcal disease. Lancet349,170–173 (1997).
- 29 Rood MJ, van Krugten MV, Zanelli E et al.: TNF-308A, HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum.43,129–134 (2000).
- 30 van der Heijde DM, van 't HM, van Riel PL, van de Putte LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J. Rheumatol.20,579–581 (1993).
- 31 Huizinga TW, Pisetsky DS, Kimberly RP: Associations, populations, and the truth: recommendations for genetic association studies in arthritis and rheumatism. Arthritis Rheum.50,2066–2071 (2004).
- 32 Newton-Cheh C, Hirschhorn JN: Genetic association studies of complex traits: design and analysis issues. Mutat. Res.573,54–69 (2005).
- 33 Cheng Q, Cheng C, Crews KR et al.: Epigenetic regulation of human γ-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am. J. Hum. Genet.79,264–274 (2006).• Demonstrates that γ-glutamyl hydrolase 452C>T is epigenetically regulated.
- 34 Hughes LB, Beasley TM, Patel H et al.: Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis.65,1213–1218 (2006).
- 35 Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG: Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int. J. Cancer103,587–599 (2003).• Descibes the importance of folylpoly-γ-glutamate synthetase to methotrexate resistance.
- 36 Kager L, Cheok M, Yang W et al.: Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J. Clin. Invest.115,110–117 (2005).• Explains that gene expression differences influence methotexate dynamics.
- 37 Barredo JC, Synold TW, Laver J et al.: Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood84,564–569 (1994).
- 38 Barredo J, Moran RG: Determinants of antifolate cytotoxicity: folylpolyglutamate synthetase activity during cellular proliferation and development. Mol. Pharmacol.42,687–694 (1992).
- 39 Whitehead VM, Vuchich MJ, Lauer SJ et al.: Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood80,1316–1323 (1992).
- 40 Galpin AJ, Schuetz JD, Masson E et al.: Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol. Pharmacol.52,155–163 (1997).
- 41 Leclerc GJ, Barredo JC: Folylpoly- γ-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues. Clin. Cancer Res.7,942–951 (2001).
- 42 Leclerc GJ, Leclerc GM, Kinser TT, Barredo JC: Analysis of folylpoly-γ-glutamate synthetase gene expression in human B-precursor ALL, T-lineage ALL cells. BMC Cancer6,132 (2006).
- 101 National Center for Biotechnology Information SNP database www.ncbi.nlm.nih.gov
